NFE2L2 and breast carcinoma: Metformin’s anticancer activities in renal and breast cancer cells have been linked to the overexpression of miR-34a, which lowers cell proliferation and the Sirt1/Pgc1/Nrf2 pathway, respectively (Do et al., 2014; Xie et al., 2017; Saini and Yang, 2018).